NVST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Envista Holdings Corp (NVST) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the financial performance in the latest quarter is impressive, the technical indicators are neutral, and there are no strong positive trading signals or news catalysts to justify an immediate buy. The stock's price trend suggests potential downside in the short term, and analysts have mixed views with a cautious outlook on the dental sector.
The technical indicators are mixed. The MACD is positive but contracting, RSI is neutral at 50.84, and moving averages are bullish. However, the stock is trading below the pivot level of 27.302, with key support at 26.414 and resistance at 28.19. The short-term stock trend indicates a 50% chance of a slight increase of 0.15% in the next day but a potential decline of -2.66% in the next week and -6.22% in the next month.
The company reported strong Q4 financials with revenue up 14.96% YoY and net income up 2641.67% YoY. Analysts have raised price targets, with some maintaining Buy or Outperform ratings. Bullish moving averages also indicate potential long-term strength.
The dental sector faces macroeconomic pressures, with analysts expecting a trade-down to lower-cost implants and orthodontics. Citi initiated coverage with a Neutral rating and a cautious outlook. The stock trend suggests potential short-term downside, and there are no recent news catalysts or significant insider or hedge fund activity.
In Q4 2025, Envista reported strong financial growth: Revenue increased by 14.96% YoY to $750.6M, net income surged by 2641.67% YoY to $32.9M, and EPS rose by 1900% YoY to $0.20. However, gross margin dropped by -3.74% YoY to 55.04%, indicating some cost pressures.
Analysts have mixed views. Recent ratings include Neutral from Citi with a $29 target, Outperform from Evercore ISI with a $30 target, and Buy from Stifel with a $31 target. The consensus highlights strong Q4 results but cautious optimism due to macroeconomic pressures on the dental sector.
